Navigation Links
TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
Date:4/10/2013

tical need for targeted treatment options for patients with difficult-to-treat solid tumors, and we look forward to further evaluating the potential of BIND-014 in patients with specific solid tumor types in the near future."

"In addition to confirming the safety, tolerability and maximum tolerated dose of BIND-014, these data also provide encouraging signs of anti-tumor activity in a variety of solid tumors," said Dr. Gregory Berk, Chief Medical Officer of BIND Therapeutics. "Based on these data, BIND is moving expeditiously to advance BIND-014 into multiple Phase 2 clinical trials in 2013 including non-small cell lung cancer, prostate cancer and bladder cancer."

BIND-014 represents the first targeted and programmable Accurin nanomedicine to reach the clinic from BIND's proprietary drug development platform, which creates targeted therapeutics designed to accumulate at the site of disease for high drug concentration and maximum therapeutic effect. BIND-014 employs a combination of a targeted biodegradable nanoparticle and docetaxel, a well-established chemotherapy agent.

Dr. Von Hoff's presentation of BIND-014 is consistent with previously reported preliminary observations in which safety, tolerability and efficacy in multiple tumor types was demonstrated:

  • BIND-014 was generally safe and well-tolerated with transient and manageable neutropenia as the dose limiting toxicity. Minimal neuropathy, mucositis, fluid retention, rash, and nail changes were observed.

  • Established the maximum tolerated dose of 60 mg/m2 when administering BIND-014 on a once every 3 week (Q3W) schedule.

  • Evidence of anti-tumor activity was shown with BIND-014 at 60mg/m2 in nine out of the 28 patients treated, ranging from one complete response (cervical cancer), three partial responses (non-small cell lung cancer, prostate and ampullary) and five patients with stabilization of disease lasting at least four cycles (> 12 week
    '/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
8. ViroPharma to Participate in Two December Healthcare Investor Conferences
9. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... results before the Nasdaq market opens on Thursday, April ... and webcast to discuss its financial results and provide ... 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... dialing 866-952-1906 (US) or 785-424-1825 (International) using the conference ...
(Date:4/23/2015)... LONDON , April 23, 2015 ... Medical Equipment   Report Details   ... reach a value of $101.3 billion in 2015 and will ... Strong growth in the healthcare sectors around the world and ... the key growth factors in the global healthcare packaging ...
(Date:4/23/2015)... 23, 2015 /PRNewswire/ - Crystal Research Associates, LLC announced ... ® (EIO) on Aeterna Zentaris Inc. (NASDAQ: ... on Crystal Research Associates, website at www.crystalra.com ... at www.aezsinc.com . Aeterna Zentaris ("Aeterna" ... company in oncology, endocrinology, and women,s health. With a ...
(Date:4/22/2015)... MN , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and ... for the first quarter 2015 on Thursday, May 7, ... has scheduled a webcast and conference call for 4.30 ... Live audio of the conference call ... available to investors, members of the news media and ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2
... whose MBA and undergraduate degree were minted at the ... Clear Software's North American operations, the company said on ... ,Cape Clear, headquartered in Massachusetts, provides "enterprise service bus" ... State of Wisconsin Department of Administraiton. , ,Though its ...
... are interested in bio and life science investments in ... Meanwhile the University of Wisconsin-Madison is introducing two new ... 30, 2005 Listen to this episode ... with companies in Madison ...
... Genzyme Corp. said on Wednesday it has agreed ... Wisconsin-Madison biotech spinoff, for $600 million in cash. , ,Bone ... more than $2 billion and almost 7,000 employees worldwide, plan ... companies recently reported healthy quarterly profits and revenues. Bone Care ...
Cached Biology Technology:Massachusetts firm to buy UW spinoff Bone Care for $600 million 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 3
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Sweden and the University of Glasgow, Scotland, has identified a ... gastrointestinal bacteria. In a study published as a letter to ... suggesting that the human genome may play a role in ... human gastrointestinal tract collectively known as the gut microbiota. ...
... a classic example of evolutionary adaptation, with beaks that vary ... While living birds have a beak to manipulate their food, ... discovery shows some fossil birds evolved teeth adapted for specialized ... a new species of early bird, Sulcavis geeorum , ...
... by senior author Morris J. Birnbaum, MD, PhD, the ... Institute for Diabetes, Obesity, and Metabolism, Perelman School of ... metformin works in a different way than previously understood. ... liver hormone glucagon,s ability to generate an important signaling ...
Cached Biology News:International study suggests human genes influence gut microbial composition 2First fossil bird with teeth specialized for tough diet 2Most-used diabetes drug works in different way than previously thought 2
... of calcium binding proteins such as calmodulin and ... alpha and beta chain whereas S100B is composed ... also expressed in the antigen presenting cells such ... reticulum cells in the paracortex of lymph nodes. ...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Polyclonal Antibody to CLAN...
Biology Products: